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1Drug-eluting stents (DES) that deliver antiproliferative drugs from a durable polymer have significantly reduced 
restenosis compared with bare metal stents.1 However, durable 
polymers may be associated with inflammation, delayed heal-
ing, and incomplete endothelialization, which may contribute 
to the risk of late (30 days to 1 year) and very late (>1 year) stent 
thrombosis compared with bare metal stents.2 Whether metal 
alloy coronary stent platforms with bioresorbable polymers are 
associated with improved clinical outcomes when compared 
with newer durable polymer DES has been the subject of 
debate3,4 and may be influenced by additional factors, includ-
ing stent strut thickness, polymer composition, distribution, 
and load.5 Although current American College of Cardiology/
American Heart of Association (ACC/AHA) clinical practice 
guidelines recommend at least 12 months of dual antiplatelet 
therapy (DAPT) after DES deployment in patients who are 
not at increased risk for bleeding,1 recent studies suggest that 
even longer duration DAPT therapy (≥30 months) provides 
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additional ischemic event reduction.6 The SYNERGY stent 
(Boston Scientific Corporation, Marlborough, MA) is a novel 
thin-strut platinum chromium (PtCr) metal alloy stent that 
elutes everolimus from an ultrathin bioabsorbable Poly(D,L-
lactide-co-glycolide) polymer applied to the abluminal surface.
The EVOLVE randomized controlled trial (EVOLVE: 
A Prospective Randomized Multicenter Single-blind Non-
inferiority Trial to Assess the Safety and Performance of 
the Evolution Everolimus-Eluting Monorail Coronary Stent 
System [Evolution Stent System] for the Treatment of a 
De novo Atherosclerotic Lesion; NCT01135225) found 
SYNERGY to be noninferior to the durable polymer PROMUS 
Element everolimus-eluting stent (EES) for the angiographic 
end point of in-stent late lumen loss at 6 months,7 but lacked 
sufficient power to provide meaningful comparison(s) of clin-
ical events.8 EVOLVE II represents the pivotal, randomized 
controlled clinical trial evaluating the clinical efficacy and 
safety of the SYNERGY stent for regulatory approval in a 
broad population of patients undergoing percutaneous coro-
nary intervention (PCI).
Methods
EVOLVE II is a prospective, international, multicenter, randomized 
(1:1 SYNERGY versus PROMUS Element Plus), controlled, single-
blind, noninferiority trial (EVOLVE RCT) conducted at 125 clinical 
sites. EVOLVE II also includes a concurrent, nonrandomized, sin-
gle-arm, pharmacokinetic substudy (EVOLVE II PK), as well as a 
consecutively enrolled, nonrandomized, single-arm, diabetes melli-
tus substudy (EVOLVE II Diabetes; Figure 1), both of which will be 
reported separately. EVOLVE II was conducted in accordance with 
the US Food and Drug Administration’s Guidance for Industry E6 
Good Clinical Practice: Consolidated Guidance, the Declaration of 
Helsinki, the International Conference on Harmonisation, and all lo-
cal regulations, as appropriate. Institutional Review Boards at each 
center approved the study protocol and all subjects provided written 
informed consent. The study is registered at www.clinicalTrials.gov 
under identifier NCT01665053.
Device Description
The SYNERGY stent is a thin-strut (74–81 μm), PtCr metal alloy 
platform with an ultrathin (4 μmol/L) bioabsorbable Poly(D,L-
lactide-co-glycolide) abluminal polymer, which elutes everolimus 
(100 μg/cm2). SYNERGY has been compared with the durable poly-
mer PROMUS Element EES as described previously9,10 (Table 1).
Study Design and Procedure
Eligible patients were aged ≥18 years and had either symptomatic 
coronary artery disease with objective evidence of ischemia or silent 
ischemia. Stents were implanted for treatment of ≤3 (maximum) 
discrete target lesions in ≤2 (maximum) 2 major epicardial vessels 
with lesion length ≤34 mm and reference vessel diameter ≥2.25 to 
≤4.0 mm. Target stenoses were ≥50% and <100% with thromboly-
sis in myocardial infarction flow >1. Subjects were required to have 
either target stenosis ≥70% or a stenosis ≥50% to <70% with abnor-
mal fractional flow reserve, elevated cardiac biomarkers, or objective 
evidence of myocardial ischemia (abnormal stress or imaging stress 
test). Patients with recent ST-segment–elevation myocardial infarc-
tion, left main disease, chronic total occlusions, vein graft disease, or 
WHAT IS KNOWN
•	Durable polymer on coronary drug-eluting stents 
may be associated with inflammation, neoathero-
sclerosis, and thrombosis.
•	Bioabsorbable polymers may facilitate healing and 
enhanced clinical safety.
WHAT THE STUDY ADDS
•	 In a prospective, multicenter randomized single-
blind trial, the Synergy stent, with a bioabsorb-
able polymer, proved noninferior to the PROMUS 
Element Plus stent for target lesion failure to 1 year.
•	This study establishes comparable clinical safety and 
efficacy of everolimus elution from a bioabsorbable 
polymer thin strut platinum chromium metal plat-
form in support of regulatory approval for this novel 
coronary stent device.
Figure 1. Patient flow and disposition in the 
EVOLVE II Trial. CTO indicates chronic total occlu-
sion; DS, diameter stenosis; ISR, in-stent restenosis 
target lesion; LM, left main; PK, pharmacokinetic; 
RVD, reference vessel diameter; STEMI, ST-seg-
ment–elevation myocardial infarction; and SVG, 
saphenous vein graft target lesion.
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in-stent restenosis were excluded per-protocol. Subjects who satis-
fied study selection criteria were randomly assigned 1:1 (stratified by 
diabetic status and enrollment site) to receive treatment with either 
SYNERGY or PROMUS Element Plus stents. Random permuted 
blocks were used to ensure approximate balance of treatment allo-
cation within each stratum. EVOLVE II RCT is a single blind trial; 
subjects were blinded to treatment assigned and treatment received 
and will remain blinded until after trial completion. Packaging of the 
investigational control and test devices was different, therefore, the 
investigator performing the procedure was not blinded to the assigned 
treatment arm or resulting treatment. Site personnel conducting clini-
cal follow-up, core laboratory personnel and the Clinical Events 
Committee were blinded to patient treatment assignment during the 
trial.
DAPT with aspirin and a P2Y12 inhibitor was prescribed after PCI 
for at least 6 months (12 months in patients not at high risk of bleed-
ing). An independent core laboratory evaluated all baseline and repeat 
angiograms (Beth Israel Deaconess Medical Center, Boston, MA). 
Clinical follow-up was required in-hospital at 30 days, 6, 12, and 18 
months after PCI then annually between 2 and 5 years. There was no 
protocol-specified coronary angiography in follow-up.
End Points
The primary end point for EVOLVE II was the rate of 12-month 
target lesion failure (TLF), defined as the composite occurrence of 
any ischemia-driven revascularization of the target lesion, myocar-
dial infarction (MI) related to the target vessel, or any cardiac death. 
Secondary clinical end points included individual components of 
TLF; target vessel failure defined as the composite occurrence of 
ischemia-driven target vessel revascularization, MI related to the 
target vessel or cardiac death related to the target vessel), all-cause 
death, and stent thrombosis (defined by the Academic Research 
Consortium; ST).11 All major adverse events were adjudicated by a 
Clinical Events Committee and the decisions of the Clinical Events 
Committee superseded those of the investigational center in the 
event of a disparity. Spontaneous MI was defined as the rise and 
fall of cardiac biomarkers with ≥1 value >99th percentile of the 
upper reference limit with evidence of myocardial ischemia. The 
diagnosis of periprocedural MI required at least 1 of the following: 
(1) CK-MB >3× upper reference limit without clinical or imaging 
correlates, (2) new pathological Q waves, or (3) autopsy evidence 
of acute MI. MI was also independently assessed by Academic 
Research Consortium criteria as a secondary analysis.11 Further 
details pertaining to the definition of MI are found in the Data 
Supplement document. Technical success was defined as success-
ful delivery and deployment of the study stent to the target vessel, 
without balloon rupture or stent embolization with postprocedure 
diameter stenosis of <30% and thrombolysis in myocardial infarc-
tion 3 flow in the target lesion (as visually assessed by the treating 
Table 1. Specific Design Characteristics of the SYNERGY and 
PROMUS Element Plus Stents
SYNERGY PROMUS Element Plus
Platform material Platinum chromium Platinum chromium
Stent strut thickness 74–81 μm 81–86 μm
Polymer 85:15 PLGA PVDF-HFP PBMA
Polymer type Biodegradable Biostable
Polymer distribution Abluminal Conformal
Polymer thickness 4 μm 7.8 μm
Polymer duration Approximately 4 mo Permanent
Drug Everolimus Everolimus
Drug/polymer ratio in active 
layer (wt%/wt%)
45/55 17/83
Loaded drug dose 100 μg/cm2 100 μg/cm2
PLGA indicates Poly(D,L-lactide-co-glycolide); and PVDF, polyvinylidene 
fluoride.
Table 2. Baseline Characteristics of the Study Population
Variable*
SYNERGY
n=846 Patients
PROMUS Element Plus
n=838 Patients P Value†
Male 70.6% 72.7% 0.34
Age, y, ±SD 63.5±10.4 63.9±10.5 0.40
White 77.4% 79.2% 0.37
Smoking, ever 61.7% 62.8% 0.63
Current smoker 21.8% 22.4% 0.76
Diabetes mellitus‡ 31.1% 30.8% 0.89
  Treated with insulin 12.3% 10.9% 0.36
Hyperlipidemia‡ 74.0% 74.5% 0.82
Hypertension‡ 77.3% 75.1% 0.29
Previous PCI 35.8% 37.3% 0.52
Previous CABG 4.6% 6.1% 0.18
History of CHF 8.3% 9.0% 0.63
Unstable angina 33.9% 34.8% 0.69
MI 25.9% 29.2% 0.12
CABG indicates coronary artery bypass graft; MI, myocardial infarction; and 
PCI, percutaneous coronary intervention.
*Number (percent) based on an intent-to-treat analysis.
†P values are 2-sided and from Student t test for continuous variables and 
the χ2.
‡Medically treated.
Table 3. Baseline Lesion Characteristics
SYNERGY
n=1059 Lesions
n=846 Patients
PROMUS Element 
Plus n=1043  
Lesions
n=838 Patients P Value*
Target lesions† 1.25±0.50 1.24±0.49 0.77
  2 lesions treated 18.6% 19.3% 0.69
  3 lesions treated 3.3% 2.4% 0.26
  >3 lesions treated 0.0% 0.1% 0.50
Target lesion location‡
  LAD 41.3% 41.5% 0.91
  LCx 25.0% 26.4% 0.48
  RCA 33.7% 32.0% 0.41
  LM 0.0% 0.1% 0.50§
RVD, mm‡ 2.62±0.49 2.63±0.50 0.63
  RVD <2.25 mm 23.9% 23.3% 0.76
MLD, mm‡ 0.89±0.35 0.89±0.36 0.99
Diameter stenosis, %‡ 66.02±12.03 66.26±11.75 0.65
Lesion length, mm‡ 14.09±7.50 13.67±7.00 0.18
  Length >20 mm 19.2% 16.7% 0.14
Modified AHA/ACC B2/C‡ 76.8% 74.3% 0.19
ACC indicates American College of Cardiology; AHA, American Heart of 
Association; LM, left main; MLD, minimum lumen diameter; and RVD, reference 
vessel diameter.
*P values are 2-sided and from Student t test for continuous variables and the 
χ2 unless indicated otherwise.
†Per patient number (percent) based on an intent-to-treat analysis.
‡Per lesion.
§Fisher exact test.
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physician). Clinical procedural success was defined as postproce-
dure diameter stenosis <30%, thrombolysis in myocardial infarction 
3 flow in all target lesions and the absence of in-hospital MI, TVR, 
or cardiac death. All procedural and follow-up (through 12 months) 
angiograms were systematically evaluated for longitudinal stent de-
formation by the independent angiographic core laboratory.
Statistical Methods
The study primary end point, powered for noninferiority, was the 
rate of 12-month TLF. A 2-group Farrington–Manning test was 
used to test the 1-sided hypothesis of noninferiority in proportions. 
Specifically, if the P value from a 1-sided Farrington–Manning 
test was <0.025 in both the intention-to-treat and per-protocol pa-
tient populations, SYNERGY would be concluded to be noninferior 
to PROMUS Element Plus. This corresponds to the 1-sided upper 
97.5% confidence bound for the difference in 12-month TLF rates 
(SYNERGY–PROMUS Element Plus) being less than the nonin-
feriority margin. On the basis of an assumed event rate in the test 
(SYNERGY) and control (PROMUS Element Plus) groups of 8.0% 
and a noninferiority margin of 4.4%; 1684 randomized subjects (842 
per group) were required (assuming a 5% attrition) to provide power 
(1-β) of 0.89. Continuous variables were estimated as mean±SD and 
compared with the Student t test. Discrete variables were reported as 
counts and percentages, and differences were assessed by means of 
the χ2 or Fisher exact tests. Cumulative event rates were estimated by 
the Kaplan–Meier method.
Results
Patients and Enrollment
Between November 2012 and August 2013, 1684 patients 
were enrolled and randomized at 125 sites in North America, 
Europe, Australia, New Zealand, Japan, and Singapore. Of 
these, 846 were randomized to SYNERGY and 838 to PRO-
MUS Element Plus (Figure 1). One-year follow-up was avail-
able in 831 (98.2%) SYNERGY and 806 (96.2%) PROMUS 
Element Plus stent–treated patients.
Table 4. Procedural Characteristics
SYNERGY
n=1059 Lesions
n=846 Patients
n=1011 Stents
PROMUS Element 
Plus n=1043 
Lesions
n=838 Patients
n=1079 Stents P Value*
Technical success† 98.3% 96.9%   0.04
Clinical procedural 
success‡
94.9% 94.3%   0.56
Stents per patient‡ 1.31±0.60 1.29±0.56   0.46
Stents per target lesion† 1.05±0.25 1.04±0.25   0.32
Total stent length 
implanted, mm†
21.45±9.04 20.81±9.16   0.11
Predilatation, %† 97.1% 98.0%   0.18
Postdilatation, %† 60.7% 61.0%   0.90
Max pressure overall, atm† 15.98±3.06 16.09±3.13   0.41
Longitudinal stent 
deformation§
0.1%║ 0.1% >0.99
*P values are 2-sided and from Student t test for continuous variables and the χ2.
†Per lesion.
‡Per patient number (percent) based on an intent-to-treat analysis.
§Per stent.
║Occurred in a PROMUS Element Plus stent used in a SYNERGY assigned patient.
Table 5. Postprocedural Angiographic Characteristics
Per Lesion
SYNERGY
n=1059 Lesions
PROMUS Element Plus 
n=1043 Lesions
P 
Value*
MLD, in-stent, mm 2.44±0.44 2.46±0.44 0.23
MLD, in-segment, mm 2.10±0.47 2.10±0.47 0.78
%DS, in-stent, % 7.19±9.16 6.55±9.71 0.12
%DS, in-segment, % 20.60±8.41 20.93±9.13 0.39
Acute gain, in-stent, mm 1.55±0.45 1.57±0.45 0.33
Acute gain, in-segment, mm 1.22±0.48 1.21±0.47 0.72
DS indicates diameter stenosis; and MLD, minimum lumen diameter.
*P values are 2-sided and from Student’s t test for continuous variables and 
the χ2.
Figure 2. Primary end point of target 
lesion failure (TLF) at 1 year. One-year 
TLF in the SYNERGY (blue) and PROMUS 
Element Plus (red) cohorts in the intent-
to-treat (A) and per-protocol (B) patient 
populations are shown on the left. On the 
right, the plot shows the difference in TLF 
between SYNERGY and PROMUS Ele-
ment Plus (black circle) with the 1-sided 
97.5% Farrington–Manning upper con-
fidence bound (UCB*) indicated by the 
error bar. The P values for noninferiority 
testing are 1-sided.
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Baseline patient clinical demographics and quantitative 
coronary angiographic characteristics were similar between 
treatment groups (Tables 2 and 3). The average age was 64 
years, 31% of subjects had medically treated diabetes mel-
litus, more than a third had unstable angina, and more than 
quarter had MI diagnosed before the index PCI (Table 2). 
More than 20% of patients in each treatment group had mul-
tilesion (≥2 lesion) PCI and ≈75% of target lesions were 
classified as AHA/ACC B2/C lesion complexity (Table 3) by 
core laboratory adjudicated quantitative coronary angiogra-
phy. Procedural characteristics (Table 4) and postprocedural 
angiographic results (Table 5) were similar between treatment 
groups with the exception that site-reported technical success 
was more frequent among SYNERGY-treated patients (98.3% 
SYNERGY versus 96.9% PROMUS Element Plus; P=0.04). 
Two instances of longitudinal stent deformation were observed 
through 12 months, both of which involved PROMUS Element 
Plus Stents; 1 in the PROMUS Element Plus arm and 1 in the 
SYNERGY arm (occurring in a PROMUS Element Plus stent 
mistakenly used during the index procedure). Compliance 
with DAPT to 6 and 12 months was 97.7% and 89.7% for 
SYNERGY and 96.9% and 87.3% for PROMUS Element 
Plus with no significant differences between stent types.
Primary End Point Analyses
The trial primary end point of TLF analyzed by intention-
to-treat was observed in 6.7% of SYNERGY and 6.5% of 
PROMUS Element Plus–treated patients (1-sided 97.5% 
Farrington–Manning upper confidence bound of 2.68%) 
P=0.0005 noninferiority (Figure 2). Per-protocol analy-
sis demonstrated TLF to be 6.4% in each treatment group 
(upper confidence bound, 2.51%; P=0.0003 for noninferior-
ity). Because both intention-to-treat and per-protocol analyses 
demonstrate P<0.025, the SYNERGY stent is determined to 
Figure 3. Time-to-event curve for the composite 
primary end point of target lesion failure (TLF) 
through 1 year. The event rates presented here were 
calculated by Kaplan–Meier methodology and com-
pared with the log-rank test. Event rate±1.5 SE. HR 
indicates hazard ratio (95% confidence intervals).
Figure 4. Time-to-event curves for the components of target lesion failure through 1 year. Target lesion failure (primary end point) is a 
composite of any cardiac death (A), target vessel-related myocardial infarction (MI; B), and clinically indicated revascularization of the tar-
get lesion (TLR; C). Event rate±1.5 SE; P value from a log-rank test.
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be noninferior to the PROMUS Element Plus stent for TLF 
at 1 year. Kaplan–Meier curves for TLF event rate occurrence 
over time were similar for both the stents (Figure 3), as were 
the individual components of TLF (Figure 4). Revasculariza-
tion event rates to 1 year were similar between stent platforms 
as well (Table 6). There were 3 definite/probable STs in the 
SYNERGY arm (0.4%) and 5 in the PROMUS Element Plus 
arm (0.6%; P=0.50). The 2 definite STs in the SYNERGY arm 
were acute (≤24 hours) and the 1 probable ST was subacute 
(6 days) postprocedure. One of the SYNERGY acute ST 
events involved a patient who was not treated with preproce-
dural aspirin. All the 5 definite/probable STs in the PROMUS 
Element Plus arm occurred subacutely (between 2 and 30 days; 
Figure 5).
Discussion
In this pivotal trial designed to support regulatory approval of 
the first bioabsorbable polymer DES available in the United 
States, the SYNERGY stent proved to be noninferior to the 
PROMUS Element Plus stent for TLF at 1 year. Furthermore, 
rates of target vessel MI, clinically indicated/ischemia-driven 
revascularization of the target lesion and stent thrombosis to 1 
year were low and similar for both stents.
These clinical observations complement the finding of 
noninferiority of SYNERGY (versus PROMUS Element) 
for quantitative coronary angiographic late lumen loss (0.10 
versus 0.15 mm, respectively) at 6 months reported from the 
EVOLVE randomized first human use trial, and provide ade-
quate sample size from which to make more definitive con-
clusions about important clinical outcomes.7,8 In this regard, 
EVOLVE II supports the premise that the safety and efficacy 
of SYNERGY are at least comparable to the predicate PtCr 
durable polymer EES.
Although polymer provides a reservoir for programmed 
drug release, it has no function after drug release is complete 
and may affect the late/very late safety and efficacy of DES. 
First generation DES polymers (EVA-BMA [SurModics, 
Minneapolis, MN] and SIBS-translute [Boston Scientific]) 
were, at times, associated with inflammation, foreign body 
giant cell reaction, negative vessel remodeling, and late 
(acquired) stent malapposition with thrombus formation.2,12,13 
Durable polymers may also contribute to delayed/incomplete 
endothelial coverage and impaired stent healing.2,14 Although 
newer durable polymers may have enhanced biocompatibility 
and seem to be associated with improved clinical outcomes, 
they have still been incriminated in the occurrence of inflam-
mation, neoatherosclerosis, and thrombosis.15,16 Indeed, neo-
atherosclerosis occurs earlier and with increased prevalence 
after DES compared with bare metal stents and has been 
observed with similar frequency among both first as well as 
newer generation DES.17 Early randomized controlled clinical 
trials as well as meta-analyses suggested that biodegradable 
polymer DES were associated with lower rates of late/very 
late stent thrombosis when compared with either first genera-
tion DES or bare metal stents.4,18 Conversely, more recent net-
work meta-analyses and observational studies have suggested 
that the newer generation cobalt chromium (CoCr) and PtCr 
durable polymer (polyvinylidene fluoride) EES are associ-
ated with even lower rates of stent thrombosis when com-
pared with other durable polymer DES, early biodegradable 
polymer DES, and even bare metal stents.3,19–21 Furthermore, 
a randomized controlled clinical trial comparing the CoCr 
EES with its corresponding bare metal stent platform demon-
strated lower rates of stent thrombosis at 1 and 2 years after 
primary PCI for ST-elevation MI in the CoCr EES group.21 
These observations are consistent with bench and preclinical 
data, which suggest that the durable polyvinylidene fluoride 
polymer may be thromboprotective against stent thrombosis.22 
Finally, a large-scale randomized controlled trial comparison 
of the CoCr EES versus the Nobori biodegradable polymer 
Table 6. Clinical End Points Through 12 Months
Variable*
SYNERGY
n=846 Patients
PROMUS Element Plus 
n=838 Patients P Value†
Death, % 1.1% (9/832) 1.1% (9/808) 0.95
Cardiac death, % 0.5% (4/832) 0.9% (7/808) 0.34
MI, % 5.4% (45/832) 5.0% (40/808) 0.68
 Q-wave MI 0.2% (2/832) 0.2% (2/808) >0.99‡
 Non–Q-wave MI 5.2% (43/832) 4.7% (38/808) 0.66
TVR, % 3.8% (32/832) 3.6% (29/808) 0.78
 PCI, % 3.0% (25/832) 3.2% (26/808) 0.80
 CABG, % 0.8% (7/832) 0.4% (3/808) 0.34‡
TLR, % 2.6% (22/832) 1.7% (14/808) 0.21
 PCI, % 2.0% (17/832) 1.7% (14/808) 0.64
 CABG, % 0.6% (5/832) 0.0% (0/808) 0.06‡
Non-TLR TVR, % 1.8% (15/832) 2.2% (18/808) 0.54
 PCI, % 1.4% (12/832) 1.9% (15/808) 0.51
 CABG, % 0.4% (3/832) 0.4% (3/808) >0.99‡
Stent thrombosis, %§
  Definite/probable 0.4% (3/832) 0.6% (5/808) 0.50‡
  Definite 0.2% (2/832) 0.2% (2/808) >0.99‡
  Probable 0.1% (1/832) 0.4% (3/808) 0.37‡
CABG indicates coronary artery bypass graft; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; and TLR, revascularization of the target lesion.
*Binary event rates. Number (percent) based on an intent-to-treat analysis.
†P value from χ2 test unless otherwise noted.
‡P value from Fisher exact test.
§Stent thrombosis adjudicated according to Academic Research Consortium 
definition.
Figure 5. Stent thrombosis through 12 months. Definite/probable 
stent thrombosis rates through 12 months. Timing is separated into 
acute (≤1 day; blue), early (2–30 days; green), and late (>30 days– 
1 year; orange). Binary event rate; P value from a χ2 test.
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DES demonstrated similar long-term outcomes for both the 
stents.23 These apparent inconsistencies may, at least in part, 
be explained by differences in biodegradable polymer DES 
platform design.
Both the time course and extent of endothelial stent cover-
age, as well as the function and maturation of endothelial cells 
may be influenced by multiple factors, including metal alloy, 
stent strut thickness, polymer composition, and distribution as 
well as the time course for polymer bioresorption.5,24,25 In this 
regard, the SYNERGY stent was designed to enhance/expe-
dite stent healing in hopes of improving clinical outcomes 
by incorporating thin (74 μm) PtCr struts with an ultrathin (4 
μm) Poly(D,L-lactide-co-glycolide) everolimus-eluting poly-
mer applied only to the abluminal stent surface and which is 
resorbed within 4 months.7,26 The bare metal PtCr platform 
which remains after polymer resorption may be less proin-
flammatory in cell assay when compared with gold, CoCr, 
or cobalt nickel alloy platforms, and seems to both expedite 
endothelial cell stent coverage and reduce platelet adhesion 
when compared with PtCr covered by polyvinylidene fluo-
ride durable polymer.25 Whether these putative preclinical 
attributes of the SYNERGY stent may translate into clinical 
benefit (reduction in stent related ischemic events or the rela-
tive treatment benefit recently observed for longer-term DAPT 
therapy6) will require further study.
Limitations
Several potential limitations to this study deserve mention. 
First, because the study design was single-blind (patient), 
physician operators were not blinded with respect to stent 
type deployed. Second, EVOLVE II is not adequately pow-
ered to evaluate the individual components of TLF. Third, spe-
cific complex patient and target lesion subsets were excluded 
from the study (ST-segment–elevation myocardial infarction, 
left main or saphenous vein graft target stenosis, chronic total 
occlusion, in-stent restenosis). Despite the lack of all-comers 
inclusion criteria the study population seems to reflect cur-
rent clinical PCI practice with regard to the number of lesions/
vessels undergoing PCI, target lesion length and angiographic 
complexity.27 Finally, current follow-up duration is limited 
to only 1 year. Indeed, longer follow-up in more complex 
patient/lesion subsets may better differentiate between stent 
platforms with different structural design or polymer-healing 
attributes. Previous studies comparing DES with bioresorb-
able and durable polymers have, at times, demonstrated pro-
gressive differences in clinical outcomes >1 year.18
Conclusions
The EVOLVE II randomized controlled trial demonstrates the 
SYNERGY coronary stent to be noninferior to the predicate 
PROMUS Element Plus stent for the occurrence of TLF at 
1 year. Secondary end points, including ischemia-driven– 
revascularization of the target lesion and ST, were also similar 
between stents. EVOLVE II establishes comparable clinical 
safety and efficacy of everolimus elution from a bioresorb-
able polymer—PtCr metal platform when compared with 
the established PtCr durable polymer EES. The longer-term 
relative efficacy and safety of SYNERGY will be evaluated in 
5-year follow-up.
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Reginald Low University of California, Davis Medical Center Sacramento, CA USA 3 
Abram Rabinowitz Methodist Texsan Hospital San Antonio, TX USA 3 
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Robert Hodson Providence Portland Medical Center Portland, OR USA 3 
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Michael Isaac Medical City Dallas Hospital Dallas, TX USA 2 
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Manish Parikh Columbia University Medical Center New York, NY USA 1 
Barry Cohen Morristown Memorial Hospital Morristown, NJ USA 1 
Sergio Waxman Lahey Clinic Hospital Burlington, MA USA 1 
Irene Lang Allgemeines Krankenhaus AKH Vienna, Austria 1 
Didier Carrie Centre Hôpital Universitaire Rangueil Toulouse, France 1 
Adam Witkowski National Institute of Cardiology Warsaw, Poland 1 
Carey Kimmelstiel Tufts Medical Center Boston, MA USA 1 
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Supplemental Methods 
Definition of MI 
In the EVOLVE II trial, MI will be defined according to the EVOLVE II definition and the 
Universal definition provided below. The EVOLVE II definition for MI will be used for the 
primary endpoint. 
 
 
 
  
 
 
EVOLVE II Definition 
Spontaneous MI: Detection of rise and/or fall of cardiac biomarkers (CK-MB or troponin) with 
at least one value above the 99th percentile of the upper reference limit (URL) together with 
evidence of myocardial ischemia with at least one of the following: 
 Symptoms of ischemia; 
 ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch 
block [LBBB]); 
 Development of pathological Q waves in the ECG; 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
Percutaneous Coronary Intervention-Related Myocardial Infarction 
Peri-PCI MI is defined by any of the following criteria. Symptoms of cardiac ischemia are not 
required. 
i. Biomarker elevations within 48 hours of PCI: 
 CK-MB > 3X URL or 
 CK-MB not measured and CK > 2X URL or 
 Neither CK-MB nor CK measured and troponin > 3X URL  
and no evidence that cardiac biomarkers were elevated prior to the procedure OR both of the 
following must be true: 
 ≥ 50% increase in cardiac biomarker result 
 Evidence that cardiac biomarker values were decreasing (e.g., two samples 3-6 hours 
apart) prior to the suspected MI 
ii.    New pathological Q waves 
iii.   Autopsy evidence of acute MI 
Coronary Artery Bypass Grafting-Related Myocardial Infarction 
Peri-CABG MI is defined by the following criteria.  Symptoms of cardiac ischemia are not 
required. 
i. Biomarker elevations within 72 hours of CABG: 
 Troponin or CK-MB (preferred) > 5X URL and 
  
 
 
 No evidence that cardiac biomarkers were elevated prior to the procedure OR both of 
the following must be true: 
 ≥50% increase in the cardiac biomarker result 
 Evidence that cardiac biomarker values were decreasing (e.g., two samples 3-
6 hours apart) prior to the suspected MI. 
AND 
 One of the following: 
o New pathological Q-waves persistent through 30 days 
o New persistent non-rate-related LBBB 
o Angiographically documented new graft or native coronary artery occlusion 
o Other complication in the operating room resulting in loss of myocardium 
o Imaging evidence of new loss of viable myocardium 
OR 
ii. Autopsy evidence of acute MI 
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